A similar pattern of results was observed in patients with KRAS G12C–positive cancer: median OS was significantly shorter in patients with mSTK11-mKEAP1 vs STK11 WT-KEAP1 WT (6.4 vs 15.0 months; aHR, 1.93; 95% CI, 1.35–2.75; p < 0.001) (Fig. 4B). Here, KRAS is linked to cancer.